8.7
Excellent
376 reviews
- Communication
- 8.8
- Timeliness
- 8.9
- Accuracy
- 7.6
- Staff
- 8.8
- Value
- 8.9
Santos Fahey
9
- - Biomarker Development
- - 12 weeks October 2023 - January 2024
- - Research Institution
Reviewed:
Efficient and precise biomarker development.
The biomarker development project was managed efficiently, with precise results that met our project objectives. The team's expertise in biomarker research was invaluable, and we were impressed with the quality of the deliverables.
Nathan Morissette
9.4
- - Health Technology Assessment
- - 10 weeks September - November 2023
- - Pharmaceutical Company
Reviewed:
Thorough and insightful health technology assessment.
The health technology assessment was thorough and provided valuable insights that were critical to our decision-making process. The team demonstrated a deep understanding of the health economics involved and delivered a well-rounded analysis.
Kelli Fritsch MD
8.6
- - Patient Engagement
- - 8 weeks August - September 2023
- - Clinical Research Organization
Reviewed:
Impressive patient engagement strategies, significant improvement in recruitment rates.
The patient engagement strategies implemented were impressive and led to a significant improvement in our recruitment rates. The team's experience in patient-centered approaches was evident and made a real difference.
Caleb Simonis
9.3
- - Market Access Strategy
- - 6 weeks January - February 2024
- - Pharmaceutical Company
Reviewed:
Strategic market access analysis, insightful recommendations.
The market access analysis provided strategic insights that were crucial to our launch strategy. The team's recommendations were data-driven and actionable, helping us to make informed decisions.
Miguel Parisian
8.9
- - Stability Studies
- - 18 months January 2023 - June 2024
- - Pharmaceutical Company
Reviewed:
Accurate and reliable stability studies, clear reporting.
The stability studies were conducted with precision, and the reporting was clear and thorough. The results provided us with the necessary data to proceed with our regulatory submissions confidently.
Amos Bogan
5.7
- - Project Management
- - 12 weeks March - May 2024
- - Biotech Company
Reviewed:
Poor communication and missed deadlines caused frustration.
Communication from the project management team was poor, with frequent missed deadlines. This caused significant frustration on our end, as we had to repeatedly chase them for updates. The project eventually got back on track, but the delays were problematic.
Lynne Nienow
9
- - Clinical Protocol Design
- - 6 weeks April - May 2023
- - Pharmaceutical Company
Reviewed:
Comprehensive protocol design, very detailed and precise.
The protocol design provided was comprehensive and very detailed. It laid a strong foundation for our clinical trial, ensuring that all regulatory and ethical considerations were addressed. The attention to detail was impressive.
Anthony Abbott
9.2
- - Regulatory Strategy Consulting
- - 4 weeks July - August 2024
- - Biotech Startup
Reviewed:
Thorough and strategic regulatory strategy consulting.
The regulatory strategy consulting services were thorough and provided us with a clear pathway to regulatory approval. The team's deep understanding of the regulatory landscape was invaluable, and their strategic advice was spot on.
